Assistant Professor, Medicine, Vanderbilt University School of Medicine
Oncology
Dr. Laura W. Goff, MD
|
|
Give Review
Dr. Laura W. Goff is an expert in the field of Oncology. She researched medicine at University of Texas Southwestern Medical School. She received awards:"Meaningful Use Stage 1 Certification". Laura Goff is a published physician. She has 18 publications published. The most current publication "Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors." Dr. Laura W. Goff accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation...
- Decoding hepatocellular carcinoma: the promise of microRNAs.
- Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
- Current Therapy and Future Directions in Biliary Tract Malignancies.
- Advances in the management of biliary tract cancers.
- Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
- Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma.
- Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy.
- The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma.
- Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine.
- Aurora kinase inhibitors--rising stars in cancer therapeutics?
- Chemotherapy and immunotherapy in metastatic colorectal cancer.
- NCCN clinical practice guidelines in oncology: hepatobiliary cancers.
- A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies.
- Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers.
- Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.
Procedures Preformed
- Thoracentesis
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Meaningful Use Stage 1 Certification
Education
-
Vanderbilt University -
University of Texas Southwestern Medical School -
University of Texas Medical School
Hospital
-
Vanderbilt Hospital and Clinics
Helpful Reviews
Similar Doctors
|
Dr. Karl M. Rogers, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine M. Lovly, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Kenneth R. Hande, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Natalie R. Dickson, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Vicki L. Keedy, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|